Outcome of Radiation Monotherapy for High-risk Patients with Stage I Esophageal Cancer by Shirakawa, Yasuhiro et al.
S urgical resection is the current primary treatment for esophageal cancer.  In Japan,  the standard 
treatment for stage II and III esophageal cancer is pre-
operative chemotherapy with surgical resection [1].  
Esophageal cancer surgery is one of the most invasive 
surgeries because it requires a procedure involving 3 
regions (cervical,  thoracic,  and abdominal regions) 
and includes extensive lymph node dissection.  
Published reports state that esophageal cancer surgery is 
associated with a higher incidence of complications and 
perioperative mortality than any other type of cancer 
surgery [2 , 3].  In recent years,  endoscopic surgery has 
been introduced in an attempt to reduce the invasive-
ness of esophageal cancer surgery,  and several reports 
have described the effectiveness of this approach [4-7].  
On the other hand,  esophageal cancer often develops in 
elderly individuals,  often among those with a signifi-
cant drinking and/or smoking habit,  and endoscopic 
surgery has been performed in such patients for safer 
surgical resection.  Nevertheless,  there are patients who 
require nonsurgical treatment because they are very 
elderly or have severe vital organ dysfunction.  At the 
present time,  chemoradiotherapy (CRT) is the standard 
nonsurgical treatment to preserve the esophagus in 
patients with a relatively good general condition.  
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Currently,  chemoradiation is the most widely used nonsurgical treatment for esophageal cancer.  However,  
some patients,  particularly the very elderly or those with severe vital organ dysfunction,  face difficulty with the 
chemotherapy component.  We therefore examined the outcome of radiation therapy (RT) alone for patients 
with esophageal cancer at our facility.  Between January 2005 and December 2014,  84 patients underwent RT at 
our hospital,  and 78 of these patients received concomitant chemotherapy.  The remaining 6 patients under-
went RT alone; these patients were considered to be high-risk and to have no lymph node metastasis (stage I).  
Five of them received irradiation up to a curative dose: 4 showed a complete response (CR) and 1 showed a 
partial response (PR).  Of the patients exhibiting CR,  3 are currently living recurrence-free,  whereas 1 patient 
underwent endoscopic submucosal dissection (ESD) as salvage therapy for local recurrence,  with no subse-
quent recurrence.  High-risk stage I esophageal cancer patients can be treated radically with RT alone under 
certain conditions.  In the future,  to broaden the indications for RT monotherapy to include some degree of 
advanced cancers,  a novel concurrent therapy should be identified.
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However,  in high-risk patients,  such as those men-
tioned above,  CRT may lead to issues such as more 
acute adverse reactions than radiation therapy (RT) 
alone [8].  Therefore,  in patients in whom concurrent 
chemotherapy is difficult,  RT monotherapy has been an 
important treatment method.  Moreover,  if the indica-
tion for monotherapy is appropriately selected on the 
basis of accurate preoperative diagnostic imaging,  then 
RT alone can be expected to be curative in some cases 
[8].  We therefore retrospectively examined the back-
grounds and therapeutic outcomes of high-risk patients 
with esophageal cancer who were undergoing curative 
RT as monotherapy at our facility.
Patients and Methods
Patients. During the 10-year period from 
January 2005 through December 2014,  84 patients with 
esophageal cancer underwent curative RT at our facility.  
Of these,  60 patients received CRT with concurrent 
intravenous chemotherapy using a normal combination 
of 5-fluorouracil (5-FU) and cisplatin (FP therapy) or a 
combination of docetaxel,  cisplatin,  and 5-fluorouracil 
(DCF therapy); 18 patients showed organ failure 
including renal dysfunction and therefore received CRT 
with the concurrent oral anticancer agent TS-1 (tegafur,  
gimeracil,  and oteracil potassium); the remaining 6 
patients received RT alone because concurrent treat-
ment with anticancer agents was difficult (Fig. 1).  In the 
present study,  we examined the background character-
istics and therapeutic outcomes of these 6 patients.  This 
retrospective study was performed in accordance with 
the ethical standards laid down in the Helsinki 
Declaration of 1975,  as revised in 2000 and 2008 con-
cerning Human and Animal Rights.  The confidentiality 
and privacy of the patients were protected in the pre-
sentation of research results,  and no information 
obtained from this study was used for any other pur-
pose.  This study was approved by the Ethics Committee 
of Okayama University Hospital (1605-512).
Treatment. Three-dimensional conformal RT 
based on computed tomography (CT) images using 
6-10 MV X-rays was administered at a dose of 54-66 Gy 
in 27-33 fractions over 6-7 weeks.  Clinical target vol-
ume (CTV) 1 was defined as the region covering the 
primary lesion with a 3-cm margin in a craniocaudal 
direction and the regional lymph node area detected 
using endoscopy,  CT,  and 18F-fluorodeoxyglucose 
(FDG) positron emission tomography (PET)/CT.  
CTV2 was defined as the region covering the primary 
lesion with 2-cm and 0.5-cm margins in the craniocau-
dal and lateral directions,  respectively,  and the 
involved lymph nodes.  Planning target volume (PTV) 1 
and PTV2 were defined as the regions covering CTV1 
and CTV2,  respectively,  with an adequate margin to 
facilitate respiratory movements and error in reproduc-
ing patient fixation.  In PTV1,  irradiation was per-
formed up to 40 Gy with anterior/posterior opposed 
portals.  In PTV2,  irradiation was performed up to the 
planned radiation dose with bilateral oblique (off-cord) 
portals.
Follow-up. After treatment,  follow-up was con-
ducted on an outpatient basis once every 3 months,  
including a physical examination and blood tests,  
including those for tumor markers.  Alternating 
3-month periods of contrast-enhanced CT and FDG-
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Fig. 1　 Eighty-four patients who underwent radiation therapy at our facility.
PET/CT were performed during the first year.  In the 
second and subsequent years,  either contrast-enhanced 
CT or FDG-PET/CT was performed every 6 months.  In 
addition,  endoscopy was performed every 6 months.
Description and statistical analysis. Clinico-
pathological factors were noted according to the Union 
for International Cancer Control (UICC) Tumor Nodes 
Metastasis (TNM) Classification of Malignant Tumors,  
7th edition [9].  Postoperative complications were cate-
gorized according to the Clavien–Dindo classification 
[10].  All analyses were performed using JMP version 11 
statistical analysis software (SAS Institute,  Cary,  NC,  
USA).
Results
All 6 patients undergoing RT alone were male,  with 
a mean age of 69.8 years (range: 39-82 years).  All 
patients had squamous cell carcinoma,  with stage IA in 
3 patients and stage IB in 3 patients.  No patients had 
lymph node metastasis.  RT monotherapy was used in 2 
patients due to renal dysfunction,  in 2 patients due to 
liver dysfunction,  and in 3 patients due to very 
advanced age.  Treatment was discontinued in 1 patient 
because of complications during treatment that exacer-
bated the underlying disease,  chronic obstructive pul-
monary disease.  The remaining 5 patients received 
irradiation up to the scheduled curative dose (Table 1).  
There were no RT-related complications during the 
acute phase or the last stage.  Treatment was successful 
in all 5 patients who received irradiation up to the 
scheduled curative dose (CR: 4 patients; PR: 1 
patient).  Of the 4 patients with CR,  3 patients did not 
develop recurrence,  but another patient developed local 
recurrence and consequently underwent ESD as salvage 
therapy.  Thereafter,  no evidence of recurrence was 
observed.  The patient with PR developed regrowth of 
the primary lesion,  and lymph node metastasis 
appeared outside the irradiation range.  The primary 
lesion was treated with repeated argon plasma coagula-
tion (APC) but without adjuvant chemotherapy.
Case presentation. A patient who,  despite 
achieving CR by RT alone,  developed localized recur-
rence 13 months later and underwent ESD as salvage 
therapy is presented.  The patient was an 81-year-old 
man who was examined at a local clinic with a chief 
complaint of bloody stool.  Therefore,  upper and lower 
gastrointestinal endoscopy was performed,  revealing an 
irregular,  protruding tumor (type 1) in the lower intra-
thoracic esophagus,  which was confirmed to be squa-
mous cell carcinoma on biopsy (Fig. 2A , B,  and C).  
Advanced cancer was observed in the sigmoid colon,  
which was diagnosed as adenocarcinoma on biopsy.  
FDG-PET/CT revealed uptake in the tumor area.  
Laparoscopic curative resection was performed for the 
sigmoid colon cancer,  but the patient refused surgery 
for the esophageal cancer.  Therefore,  considering the 
patient’s age,  RT alone at a dose of 60 Gy was adminis-
tered to the intrathoracic esophagus only (Fig. 2D and 
E).  The patient progressed with no particular complica-
tions,  and irradiation was completed up to the sched-
uled curative dose.  Therefore,  CR was confirmed 
(Fig. 2F, G,  and H).  Thereafter,  regular endoscopic 
tests were performed,  but endoscopy performed 13 
months after RT revealed localized recurrence 
(Fig. 3A , B,  and C).  The lesion was diagnosed to be 
confined to the mucosa and was removed en bloc by ESD 
as salvage therapy (Fig. 3D, E,  and F).  Pathological 
examination of the resected specimen revealed curative 
resection of intramucosal cancer.  There was no subse-
quent recurrence.
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Table 1　 Five cases that have completed radiation therapy alone
Case No. Age/Sex TNM Stage RT dose (Gy) Response Recurrence
Time to PD
(Recurrent site)
Additional treatment Prognosis Residual tumor
1 64/M T1N0M0 StageⅠA 54 CR － － None 12M alive －
2 76/M T1N0M0 StageⅠA 66 CR － － None 58M dead －
3 39/M T2N0M0 StageⅠB 60 PR ＋ 3M
(local & distant)
APC 60M alive ＋
4 82/M T1N0M0 StageⅠA 66 CR － － None 48M alive －
5 81/M T2N0M0 StageⅠB 60 CR ＋ 13M (local) ESD 24M alive －
RT,  radiation therapy; CR,  complete response; PR,  partial response; PD,  progressive disease; M,  months; APC,  argon plasma coagulation; ESD,  endoscopic 
submucosal dissection.
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Fig. 2　 Endoscopy,  PET-CT ﬁndings before and after RT,  and irradiation ﬁeld of Case 5.
A,  B,  and C,  Pre-treatment ﬁndings; F,  G,  and H,  Post-treatment ﬁndings; A and F,  Normal white-light endoscopic ﬁndings; B and 
G,  NBI ﬁndings; D and E,  Irradiation ﬁeld conﬁguration.
Fig. 3　 Endoscopic 
ﬁndings at the time of 
recurrence and at the 
time of ESD of Case 5.
A,  Normal white-light 
endoscopic ﬁndings; B,  
NBI ﬁndings; C,  Iodine 
staining ﬁndings; D and 
E,  Findings at the time 
of the ESD; F,  Resected 
specimen ﬁndings.
Discussion
Esophageal cancer includes squamous cell carci-
noma,  which is highly responsive to chemotherapy and 
RT.  Consequently,  RT and CRT have been developed as 
nonsurgical treatments.  The Radiation Therapy 
Oncology Group (RTOG) of Europe and America has 
reported a well-known controlled trial of curative RT 
monotherapy and CRT (RTOG85-01).  This trial 
included patients with clinical stage T1-3,  N0-1,  M0 
intrathoracic esophageal cancer,  for whom treatment 
included a total radiation dose of 64 Gy for the RT 
monotherapy group and 4 courses of 5-FU + cis-diam-
minedichloroplatinum (II) (CDDP) chemotherapy 
concurrent with a total radiation dose of 50 Gy for the 
CRT group.  The 5-year survival rate for the RT mono-
therapy group was 0%,  whereas that for the CRT group 
was significantly higher,  at 27%.  On the basis of these 
results,  CRT has gained increasing popularity as a non-
surgical treatment method for esophageal cancer [11-
13].  However,  CRT of 50 Gy has been shown to achieve 
only a low local tumor control rate,  and thus the irradi-
ation method was subsequently amended from 2.0 Gy 
to 1.8 Gy per fraction.  Thus,  based on RTOG85-01,  
the CRT outcomes at radiation doses of 64.8 Gy (1.8 
Gy × 36 fractions) and 50.4 Gy (1.8 Gy × 28 fractions) 
were examined (RTOG94-05).  There was no difference 
in therapeutic outcomes between these 2 groups of 
patients [14].  Therefore,  the standard curative radia-
tion dose for CRT in Europe and America is currently 
set at 50.4 Gy.  In Japan,  on the other hand several 
reports indicate that irradiation at a dose of 60 Gy in 30 
fractions over 6-8 weeks is still being administered [15].  
Furthermore,  in cases with RT alone,  it is standard 
practice to administer 60-70 Gy in 30-35 fractions over 
6-7 weeks.
At all these doses,  the incidence of complications in 
the acute phase is higher when RT is combined with 
chemotherapy than when RT is used alone [17].  In par-
ticular,  with CDDP,  a key drug in chemotherapy for 
esophageal cancer,  nephrotoxicity and myelosuppres-
sion can easily cause issues.  Therefore,  when adminis-
tering CRT to elderly patients and patients with severe 
vital organ dysfunction,  we decided to administer con-
current oral anticancer agents associated with relatively 
few side effects,  such as TS-1.  In addition,  we selected 
RT monotherapy to treat patients with relatively early 
cancer up to stage II without lymph node metastasis,  in 
whom TS-1 use was still considered to be a risk.  Our 
data showed that,  among relatively early-stage patients,  
including high-risk patients,  most (5/6) received the 
standard curative dose with RT alone.  In all patients 
who received the curative dose,  the treatment was suc-
cessful: 4 patients with CR and 1 patient with PR.  Of 
the patients with CR,  3 patients with stage IA are cur-
rently living recurrence-free,  whereas 1 patient with 
stage IB underwent endoscopic submucosal dissection 
(ESD) as salvage therapy for local recurrence,  with no 
subsequent recurrence.  Recently,  there have been some 
reports about the benefit of salvage endoscopic thera-
pies including ESD for esophageal recurrent cancer after 
definitive RT [15-18].  However,  the patient with PR 
was unable to undergo adjuvant treatment; therefore,  
regrowth and distant lymph node metastasis were 
detected during the observation period.  We therefore 
consider that stage I esophageal cancer patients can be 
treated radically with RT monotherapy under certain 
conditions,  and that the keys to a radical cure are the 
absence of lymph node metastasis and the achievement 
of CR.
In the future,  to improve the effectiveness of RT in 
high-risk patients with some degree of advanced esoph-
ageal cancer,  we propose the use of a concurrent ther-
apy with few side effects to enhance the effectiveness of 
RT and to achieve CR.  An alternative to anticancer 
agents is gene therapy using viral vectors.  Among these,  
the most well known is a treatment using the p53 tumor 
suppressor gene,  which enhances radiation sensitivity 
[19].  For several years,  our department has conducted 
research and development on p53 gene therapy using 
adenovirus type 5,  and we have experimented with its 
clinical use for advanced lung cancer patients [20 , 21].  
In addition,  other reports have indicated that p53 gene 
therapy is effective for esophageal cancer [22 , 23].  We 
have developed a new gene therapy drug termed 
Telomelysin,  a tumor-selective oncolytic adenovirus.  
Telomelysin is a type 5 adenovirus that has been modi-
fied to proliferate in tumors with high telomerase activ-
ity.  Although the agent has exhibited an antitumor 
effect even when used alone [24-26],  it has been 
demonstrated on an experimental level that the anti-tu-
mor effect is further increased when combined with 
radiation [27].  The clinical application of Telomelysin 
combined with RT is eagerly awaited,  and we believe 
that esophageal cancer would be a promising candidate 
disease for this purpose,  since it has essentially high 
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sensitivity to radiation and since more than 80% of 
esophageal cancer patients exhibit enhanced telomerase 
activity.  Moreover,  we believe that the most benefit will 
be gained in high-risk patients with esophageal cancer 
in whom concurrent chemotherapy is difficult.
In conclusion,  when performed in appropriately 
selected patients with relatively early esophageal cancer,  
RT monotherapy can be expected to achieve a satisfac-
tory cure.  Moreover,  to expand the indications to 
include some degree of advanced cancers,  a novel con-
current therapy should be identified in the near future.
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